DESCRIPTION provided by applicant Even as the cost and throughput of commercial sequencers has continued to improve over the last years there is still a need to further reduce sequencing costs ...SBIR Phase I 2014 Department of Health and Human Services National Institutes of Health
DESCRIPTION (provided by applicant): The feasibility of a label-free technology, Millikan Sequencing, will be evaluated for de novo sequencing of mammalian genomes for under 1,000. This novel seque ...SBIR Phase I 2010 Department of Health and Human Services
CAERUS MOLECULAR DIAGNOSTICS, INC.
| 1644 KENSINGTON AVE
LOS ALTOS, CA, 94024-6028
|Socially and Economically Disadvantaged:||N|
|Number of Employees:||2|